{"id":206229,"date":"2017-02-08T15:35:57","date_gmt":"2017-02-08T20:35:57","guid":{"rendered":"http:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/uncategorized\/ats-automation-tooling-systems-atsaf-ceo-anthony-caputo-on-q3-2016-results-earnings-call-transcript-seeking-alpha.php"},"modified":"2017-02-08T15:35:57","modified_gmt":"2017-02-08T20:35:57","slug":"ats-automation-tooling-systems-atsaf-ceo-anthony-caputo-on-q3-2016-results-earnings-call-transcript-seeking-alpha","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/life-extension\/ats-automation-tooling-systems-atsaf-ceo-anthony-caputo-on-q3-2016-results-earnings-call-transcript-seeking-alpha.php","title":{"rendered":"ATS Automation Tooling Systems&#8217; (ATSAF) CEO Anthony Caputo on Q3 2016 Results &#8211; Earnings Call Transcript &#8211; Seeking Alpha"},"content":{"rendered":"<p><p>    ATS Automation Tooling Systems Inc. (OTCPK:ATSAF) Q3 2016    Earnings Call February 8, 2017 10:00 AM ET  <\/p>\n<p>    Executives  <\/p>\n<p>    Stewart McCuaig - VP, General Counsel  <\/p>\n<p>    Anthony Caputo - CEO  <\/p>\n<p>    Maria Perrella - CFO  <\/p>\n<p>    Analysts  <\/p>\n<p>    Cherilyn Radbourne - TD Securities  <\/p>\n<p>    Mark Neville - Scotiabank  <\/p>\n<p>    David Tyerman - Cormark Securities  <\/p>\n<p>    Justin Keywood - GMP Securities  <\/p>\n<p>    Yilma Abebe - JP Morgan  <\/p>\n<p>    Robert Caldwell - Richardson GMP  <\/p>\n<p>    Operator  <\/p>\n<p>    Good morning, ladies and gentlemen. Welcome to the ATS    Automation Third Quarter Conference Call. I would like to    remind you that this call is being recorded on February 08,    2017 at 10 AM Eastern Time. Following the presentation, we will    conduct a question-and-answer session. Instructions will be    provided at that time for you to queue up for questions.    [Operator Instructions]  <\/p>\n<p>    I'd now like to turn the call over to Stewart McCuaig, Vice    President, General Counsel of ATS.  <\/p>\n<p>    Stewart McCuaig  <\/p>\n<p>    Thanks, operator, and good morning, everyone. Your main hosts    today are Anthony Caputo, Chief Executive Officer of ATS; and    Maria Perrella, Chief Financial Officer.  <\/p>\n<p>    Before we begin, I'm required to provide the following    statement respecting forward-looking information, which is made    on behalf of ATS and all of its representatives on this call.    The oral statements made on this call will contain    forward-looking information. The actual results could differ    materially from a conclusion, forecast or projection in the    forward-looking information.  <\/p>\n<p>    Certain material factors or assumptions were applied in drawing    a conclusion or making a forecast or projection as reflected in    the forward-looking information. Additional information about    the factors that could cause actual results to differ    materially from the conclusion, forecast or projection in the    forward-looking information, and the material factors or    assumptions that were applied in drawing a conclusion or making    a forecast or projection as reflected in the forward-looking    information, are contained in HS' filings with Canadian    provincial securities regulators.  <\/p>\n<p>    Now, it's my pleasure to turn the call over to Anthony.  <\/p>\n<p>    Anthony Caputo  <\/p>\n<p>    Good morning, ladies and gentlemen. I assume you've seen our    press release. Maria will review financial highlights in a few    minutes. In the third quarter, operating performance was strong    notwithstanding with our revenues. Order bookings grew and we    continue to advance our value creation plan. Today, Ill update    you on our performance, after sales service, M&A,    conditions in the market and then Ill make some summary    comments.  <\/p>\n<p>    Starting with Q3 results, bookings were 284 million, up 25%    over Q3 last year. Year-to-date, we booked 812 million which is    almost 20% higher than last year. Of note, in Q3 the average    size of our three largest quarters was approximately $30    million, as we continue to engage with customers on a more    strategic basis, which from time-to-time results in an    enterprise order.  <\/p>\n<p>    Our backlog is strong in terms of quantity and quality, and    increasingly related to potential future orders, included in    our third quarter bookings was an approximately $40 million    initial order related to a multi-year enterprise agreement for    the supply of automated systems and related services from Bruce    Power's Life Extension Program. We executed a master supply    agreement, which provides a framework for potential additional    mortgage.  <\/p>\n<p>    Q3 revenues of $237 million were driven by project timing, the    cancel contract and some other adjustments. Adjusted earnings    margin was 9%, as higher gross margins did not fully offset    lower volumes. In December, we announced the cancellation of    the aforementioned large enterprise order due to rapid changes    in the customers market, which caused them to revaluate their    product roadmap. We are currently engaged with this customer to    determine what equipments can be repurposed for the next    generation product.  <\/p>\n<p>    Based on our discussions, we believe ATS will also provide    additional equipment beyond that which maybe repurposed for the    new requirements. From an operations perspective, we continue    to see the benefit of operational changes, implemented to    address the root causes of related programs and our gross    margin improved accordingly. We remain focused on improving    program management, enhancing the utilization of our global    footprint and improving our cost structure.  <\/p>\n<p>    Moving to after sales service, as I noted previously, customer    receptivity has been positive and our after sales service    organization has continued to advance our plans. We have a    well-defined offering and channels to take our offering to new    and existing customers. We will continue to focus on growing    this aspect of our business.  <\/p>\n<p>    On M&A, our efforts remain active as we seek to acquire    capability that we deem to be strategic and at the appropriate    price. We've seen a number of actionable targets and are also    focused on generating more. We have a strong balance sheet with    significant borrowing capacity, and we've demonstrated over the    past year the ability to generate cash flows to quickly    deliver.  <\/p>\n<p>    Turning to our markets, our funnel is significant. We are    focused on growing the funnel, which includes a number of    synergy opportunities with PA, and increasingly submitting    larger proposals, including some for enterprise-type programs.    Customer receptivity has been positive, and the frequency of    submitting enterprise proposals is increasing. In terms of our    verticals, in transportation, our funnel has grown and we    continue to see robust proposal activity and significant    opportunities in new technologies like batteries and e-motors    as well as traditional ones such as transmission and power    train.  <\/p>\n<p>    In life sciences, activity is very strong. We continue to see    numerous opportunities in both pharma and medical devices for    existing customers and new customers, which have led the    several large orders. In energy, we also have significant    opportunities. We have established a strong position in    nuclear, and we are pursuing some significant opportunities in    this market. In consumer products and electronics activities    has continued to improve particularly in consumable, durables    and industrials; however, this area remains soft relative to    other markets.  <\/p>\n<p>    In terms of outlook, our competitive position is strong.    However, as I've said before, the global economy remains    uncertain, and some customers are exercising additional caution    when it comes to their capital investments. In summary, our    third quarter performance was strong notwithstanding more    revenues. Our enterprise program strategy is well routed,    yielding clear results and the prospects are significant. After    sale services has continue to gain traction and our strong    balance sheet supports our growth strategy.  <\/p>\n<p>    As you read in this morning second press release, ATS has    appointed a new CEO, who will come on Board early March. I will    be stepping down as ATS, CEO on February 15th and resigning    from the Board. Maria will be taking over during the interim    period. In due course, the Company will create an opportunity    for Andrew to be introduced to you. On a personal note, I thank    you for your continued interest in the Company and the respect    you have afforded me and the management team. ATS is a great    company with a differentiated platform, a strong balance sheet    and a global customer base served by very talented people. ATS    has achieved a lot and is well positioned to accomplish much    more. It's been a privilege to serve as its CEO.  <\/p>\n<p>    At this point, I'd like to turn the call over to Maria.  <\/p>\n<p>    Maria Perrella  <\/p>\n<p>    Thank you, Anthony. Our operations continue to perform well in    the third quarter despite the timing of revenue generation and    the impact of the cancelled order. We're pleased with the level    of quarterly order bookings at $284 million and closing backlog    of 632 million. Although, we had cash usage of 14 million in    the quarter on a year-to-date basis, we've generated $47    million in cash from operations. Our non-cash working capital    as a percentage of revenue increased to 15.1%; however, we    expect this to decrease in the next quarter.  <\/p>\n<p>    This morning, I will discuss operating results for the quarter    and our balance sheet. I'll start with our operating results.    Q3 bookings of $284 million were similar to last Q2 bookings of    $289 million and exceeded prior year Q3 bookings of 228    million. On a year-to-date basis fiscal '17 bookings are 812    million or 19% higher than 680 million last year. Backlog was    adjusted for the cancelled programs however at 632 million is    still 16% higher than a year ago, providing a strong foundation    going forward.  <\/p>\n<p>    Q3 revenues were at $237 million or 38 million lower than Q3    last year. This primarily reflected both the timing of program    activities as a larger percentage of our programs are in early    stages, where lower revenues are typically realized and the    cancelation of the enterprise program. Also included in the    quarter were adjustments and revised estimates related to    certain programs, which have been completed or are in process.    Our gross margin in Q3 was 25.8%, up slightly from 25.5% in Q3    last year, despite lower volumes.  <\/p>\n<p>    Gross margins have been improving quarter over quarter from    24.4% in Q1 to 25% in Q2 and now 25.8% due to program execution    and the types of programs we're perusing. On a year-to-date    basis despite lower revenues of 745 million, as compared to 793    million last year, gross margins improved slightly to 25.1%    versus 24.9% last year. Better program control and    restructuring activities undertaken over the last year have    offset the revenue impact.  <\/p>\n<p>    Moving to SG&A, Q3 included restructuring charges of $2.3    million related to closing a U.S. facility. This was part of    our ongoing initiative to improve our cost structure and    consolidate capabilities, without negatively impacting    capability or capacity. On an adjusted basis excluding    amortization of acquisition-related intangibles and    restructuring charges, Q3 SG&A was $36.9 million compared    to the $36 million in each of Q2 and Q1. We expect to be in the    $35 million to $37 million range going forward.  <\/p>\n<p>    Q3 adjusted earnings from operations of $22.5 million were 9.5%    of revenue or slight improvement over Q2's 22 million and 9.2%    due to improved gross margins, which offset lower volume. Last    year Q3 adjusted earnings were $10 million higher at 32 million    and 11.7% of revenue as a result of higher revenues, which    generated the incremental earnings dollars. In Q2, we said that    if the enterprise program was to be terminated, we did not    expect any material negative impact from the cancellation    beyond Q3. This remains our view.  <\/p>\n<p>    As reported in order backlog continuity, the cancelled program    has been removed from our backlog, bringing closing Q3 backlog    to $632 million, up 16% over last year. Based on the    composition of our backlog at the end of Q3 and our estimates    of in quarter orders, which are booked and converted to revenue    in the same quarter, Q4 fiscal '17 revenues are estimated to be    in the higher end of the 35% to 40% range of backlog. Our    estimated Q4 revenues are being impacted by the timing and size    of programs one in Q2 and Q3, as we expect programs will still    be in early stages where revenues are primarily driven by labor    as compared to the assembly stage where revenues ramp up as    they include labor and third party materials.  <\/p>\n<p>    Moving to the balance sheet, Ill review cash generation and    non-cash working capital as a percentage of revenue. In Q3, we    used cash from operations of $14.1 million due to the timing of    milestone billing and payments. This is down from Q3 last year,    when we generated cash from operations of 31.6 million. On a    year-to-date basis, we generated cash from operations of 47    million compared to $2 million in the first three quarters last    year.  <\/p>\n<p>    At the end of the third quarter, our total net debt position    was a $128 million compared to prior years net debt of 208    million. This represents a reduction of debt of $80 million. We    continue to have strong liquidity with cash on hand of    approximately $204 million and a 750 million credit facility of    which approximately 650 million is available. Our capital    structure also includes a seven-year fixed interest U.S. $250    million bond. Our Q3 non-cash working capital as a percentage    of revenue is 15.1%, as compared to last year Q3 of 15.4%. We    target to be below 15%; however, expect the percentage will    fluctuate depending on opportunities, the timing of milestone    billings and payments. Fluctuation can be close in our last few    quarters where Q1 non-cash working capital as a percentage of    revenue was 10.2% then in Q2 it was 11.5% and now 15.1% due to    timing.  <\/p>\n<p>    Turning to net earnings, in Q3 we generated earnings per share    of $0.07 compared to $0.09 last quarter Q2 and $0.16 in Q3 last    year. The decrease is primarily due to lower volumes. On an    adjusted earnings per share basis, we generated $0.12 compared    to $0.13 last quarter and $0.21 in fiscal 2016, Q3. The $0.09    year-over-year decrease is primarily due to lower volumes and    increased stock compensation expense. Our effective tax rate    was 26% in Q3 and 24% year-to-date. Going forward, our    effective tax rate is expected to continue to be in the range    of 25% of pre-tax earnings.  <\/p>\n<p>    In summary, our business remains strong, our backlog is healthy    at 632 million and well provide for a strong revenue base in    the upcoming quarters. Our funnel remains well diversified with    the good mix of programs and enterprise solutions. We will    continue to focus on our frontend including pursuing enterprise    programs and growth in after sales services and delivery    initiatives including our cost structure and program management    in order to improve organic growth and margins going forward.    We have a strong balance sheet and we remain committed to our    growth and value creation plans.  <\/p>\n<p>    Now, we'd like to open the call to your questions. Operator,    could you please provide instructions to our listeners. Thank    you.  <\/p>\n<p>    Question-and-Answer Session  <\/p>\n<p>    Operator  <\/p>\n<p>    Ladies and gentlemen, we will now conduct a question-and-answer    session. To allow us many voices to be heard as possible please    limit yourself to two questions per turn. [Operator    Instructions] Your first question comes from the line of Ms.    Cherilyn Radbourne with TD Securities. Please go ahead.  <\/p>\n<p>    Cherilyn    Radbourne  <\/p>\n<p>    Thanks very much and good morning. Anthony, I wanted to extend    my best wishes if you transition here.  <\/p>\n<p>    Anthony Caputo  <\/p>\n<p>    Thank you.  <\/p>\n<p>    Cherilyn    Radbourne  <\/p>\n<p>    I wanted to ask about the $40 million order with Bruce Power    that was highlighted in the quarter. So, I was just wondering,    if you could give us more color on the potential size and    timing of the future orders?  <\/p>\n<p>    Anthony Caputo  <\/p>\n<p>    The order itself is part of whats called the major component    replacement program, which is much bigger than the order we    received. And the future depends on the really two things;    number one, the program in its entirety and the rate at which    it moves; number two, our performance; and number three, how we    fit with other participants and players on the program. It's    envisioned that we will continue to participate and thats why    we negotiated and put in place some master supply agreement in    order to allow for future potential. Its a very big program in    all and ATS is now a major player in that nuclear space.  <\/p>\n<p>    Cherilyn    Radbourne  <\/p>\n<p>    Great. And if I look at Q2 -- sorry, Q3 relative to Q2 there    was a pretty big sequential increase in your life sciences    backlog. But it doesnt sound like there was an enterprise    order booked in that segment. Maybe you can just elaborate a    little bit more on the work that you secured in life sciences    recently?  <\/p>\n<p>    Anthony Caputo  <\/p>\n<p>    Ill talk about this three that I talked about in the script.    One order has to do with a critical respiratory product, which    is multi-dose dry powder inhaler, and it's for three lines with    a bridge to a fourth line, AND you would recognize the name of    the customer. The second one, you would also recognize the name    of the customer has to do with infusion, and this is a repeat    customer for which we built two lines before. And this is a    closed IV the system with tube in connection. It's a fairly    high growth product and the customers demand is such that he    needs to hurry up to pick more to market and future systems are    possible.  <\/p>\n<p>    Another one which is kind of interesting has to do with PA,    which is a customer that is establishing a facility and    upgrading capability in the U.S., and it's the retrofit of    biotech site. This is going to manufacture two drugs, one for    Crohn's and colitis, and the second one for cancer. And like I    said, it's the first U.S. site for this particular company, and    we PA are designing and upgrading and implementing testing,    automation process controls and commissioning and    qualification.  <\/p>\n<p>    Cherilyn    Radbourne  <\/p>\n<p>    That's a nice color. Thank you. And then last one from me for    Maria. I just wanted to pick up on your comments regarding the    gross margin performance in the quarter. Can you tell us how    much you would attribute to better execution versus mix of work    that was being revenued in the quarter?  <\/p>\n<p>    Maria Perrella  <\/p>\n<p>    I'd say it's all due to better execution. I'd say two about or    last quarter for sure we have death with most of read programs.    And therefore, we're not seeing the impact of those. And as far    as work in our backlog goes, we have a good mix of better    margin work, and we started to see that in Q2; and then in Q3,    we had more benefit of that plus a slightly better performance.  <\/p>\n<p>    Operator  <\/p>\n<p>    Your next question comes from Mark Neville from Scotiabank.    Your line is open.  <\/p>\n<p>    Mark Neville  <\/p>\n<p>    Just first question for Anthony. Curious as to you're involved    into the selection of the new CEO and I guess to that extent    sort of why you may feel that Andrew might be the right person    to lead the Company going forward?  <\/p>\n<p>    Anthony Caputo  <\/p>\n<p>    I had peripheral involvement in the process and I think like I    said in the script, we, the Company will create an opportunity    for Andrew to be more formally introduced, and then at that    occasion, I think the best person to talk about process and    outcome, and it was an extensive process and it was an global    process would be David, who is of course our Chairman. And then    the best person to talk about Andrew and his fit and his    background and on his steps going forward is Andrew, so I    wouldnt want to steal the show from those two.  <\/p>\n<p>    Mark Neville  <\/p>\n<p>    Fair enough. Thank you. I guess just a follow-up on the Bruce.    I'm just curious the master supply agreements, the term of    that, again I think this investment to the Bruce Power program    runs through 2064. So I'm just curious to how longer there    supply agreement, I think most investment come for 2020 is    well. So, just curious is to the length for the term of your    agreement?  <\/p>\n<p>    Anthony Caputo  <\/p>\n<p>    I got to check, so I dont get it wrong. It's not 20 years and    it's not one, but it's intended to parallel the life of the    program, but before we hang up, I'm going to give you the right    number.  <\/p>\n<p>    Mark Neville  <\/p>\n<p>    Sure thanks. I just want to follow up on the gross margin as    well. So, I guess Maria from what's I am hearing correctly, mix    was a necessary onetime benefit in the quarter, it's just    better execution. So, just on the go forward basis or maybe    some variability, but there is not necessary reason to take a    big step down as a sort of that way you care for your comments?  <\/p>\n<p>    Maria Perrella  <\/p>\n<p>    Yes, thats a good way to interpret.  <\/p>\n<p>    Anthony Caputo  <\/p>\n<p>    And I think just -- as I could differentiate between mix and    nature of programs.  <\/p>\n<p>    Mark Neville  <\/p>\n<p>    All right.  <\/p>\n<p>    Anthony Caputo  <\/p>\n<p>    So, I think a lot has to do with the nature; as programs get    bigger, and we control more elements. If we get in trouble in    one aspect of the program, we have another aspect of the    program that we can use within the program itself to get    healthy. So, its a function of mix but it's also a function of    nature.  <\/p>\n<p>    Mark Neville  <\/p>\n<p>    Okay, that makes sense, I think I get that. And may be just one    last one, on the 70 million backlog that was cancelled, I    believe you said in your press release in December there, the    vendor or the customer would be -- may be procuring new    equipments early '17 or mid '17. And I'm just curious if there    is any update on that if they start to procure equipment or    again anything you can say that out?  <\/p>\n<p>    Anthony Caputo  <\/p>\n<p>    Sorry, do you want?  <\/p>\n<p>    A - Maria Perrella  <\/p>\n<p>    No.  <\/p>\n<p>    Anthony Caputo  <\/p>\n<p>    We've submitted a number of proposals on the repurposing, and    we've submitted a number of proposals on equipment in addition    to the repurposing. So, I think the timeline is that we gave    before is still right.  <\/p>\n<p>    Operator  <\/p>\n<p>    Your next question comes from David Tyerman from Cormark    Securities. Your line is open.  <\/p>\n<p>    David Tyerman  <\/p>\n<p>    So just may be going to the filler again. Do you have any kind    of magnitude that we could be thinking about? Is this replacing    the something possible or something you can resize the original    100 or is this going to be much smaller opportunity?  <\/p>\n<p>    Maria Perrella  <\/p>\n<p>    At this time we believe that, it won't be or the opportunity    won't be similar to the original opportunity. Probably more in    line with the cancelled backlog and that has to do with the    repurposing of a lot of the material that we used in the    original 100 million U.S. order.  <\/p>\n<p><!-- Auto Generated --><\/p>\n<p>Continued here:<\/p>\n<p><a target=\"_blank\" rel=\"nofollow\" href=\"http:\/\/seekingalpha.com\/article\/4043901-ats-automation-tooling-systems-atsaf-ceo-anthony-caputo-q3-2016-results-earnings-call\" title=\"ATS Automation Tooling Systems' (ATSAF) CEO Anthony Caputo on Q3 2016 Results - Earnings Call Transcript - Seeking Alpha\">ATS Automation Tooling Systems' (ATSAF) CEO Anthony Caputo on Q3 2016 Results - Earnings Call Transcript - Seeking Alpha<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> ATS Automation Tooling Systems Inc.  <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/life-extension\/ats-automation-tooling-systems-atsaf-ceo-anthony-caputo-on-q3-2016-results-earnings-call-transcript-seeking-alpha.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[431585],"tags":[],"class_list":["post-206229","post","type-post","status-publish","format-standard","hentry","category-life-extension"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/206229"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=206229"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/206229\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=206229"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=206229"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=206229"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}